Overcoming challenges for development of amorphous powders for inhalation

References

• Chan JG, Wong J, Zhou QT, et al. Advances in device and formulation technologies for pulmonary drug delivery. AAPS PharmSciTech. 2014 Aug;15(4):882–897.
   PubMed Web of Science ®Google Scholar
• Kwok PC, Chan HK. Delivery of inhalation drugs to children for asthma and other respiratory diseases. Adv Drug Deliv Rev. 2014;73:83–88.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1–2):1–19.
   PubMed Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209–1227.
   PubMedGoogle Scholar
• Zhou QT, Tang P, Leung SS, et al. Emerging inhalation aerosol devices and strategies: where are we headed? Adv Drug Deliv Rev. 2014;75:3–17.
   PubMed Web of Science ®Google Scholar
• Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J. 1999;14(3):678.
   PubMed Web of Science ®Google Scholar
• Anderson SD, Daviskas E, Brannan JD, et al. Repurposing excipients as active inhalation agents: the mannitol story. Adv Drug Deliv Rev. 2018;133:45–56.
   PubMed Web of Science ®Google Scholar
• Kwok PCL, Chan H-K. Advances in pulmonary drug delivery. Boca Raton (FL): CRC Press; 2016.
   Google Scholar
• Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013;27(6):479–489.
   PubMed Web of Science ®Google Scholar
• Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care. 2004;27(10):2356.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14(4):499–512.
   PubMed Web of Science ®Google Scholar
• Weers JG, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin Drug Deliv. 2007;4(3):297–313.
   PubMed Web of Science ®Google Scholar
• Chan H-K, Clark A, Gonda I, et al. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res. 1997;14(4):431–437.
   PubMed Web of Science ®Google Scholar
• Chan H-K, Chew NYK. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev. 2003;55(7):793–805.
   PubMed Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999–1022.
   PubMed Web of Science ®Google Scholar
• Weers JG, Miller DP. Formulation design of dry powders for inhalation. J Pharm Sci. 2015;104(10):3259–3288.
   PubMed Web of Science ®Google Scholar
• Chew NYK, Chan H-K. Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols. Pharm Res. 1999;16(7):1098–1103.
   PubMed Web of Science ®Google Scholar
• Chan H-K, Kwok PCL. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev. 2011;63(6):406–416.
   PubMed Web of Science ®Google Scholar
• Reverchon E, De Marco I, Torino E. Nanoparticles production by supercritical antisolvent precipitation: A general interpretation. J Supercrit Fluids. 2007;43(1):126–138.
   Web of Science ®Google Scholar
• Bustami RT, Chan HK, Dehghani F, et al. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm Res. 2000;17(11):1360–1366.
   PubMed Web of Science ®Google Scholar
• Chen J-F, Zhang J-Y, Shen Z-G, et al. Preparation and characterization of amorphous cefuroxime axetil drug nanoparticles with novel technology:  high-gravity antisolvent precipitation. Ind Eng Chem Res. 2006;45(25):8723–8727.
   Web of Science ®Google Scholar
• Zhong J, Shen Z, Yang Y, et al. Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment. Int J Pharm. 2005;301(1):286–293.
   PubMedGoogle Scholar
• Zhao H, Wang J-X, Wang Q-A, et al. Controlled liquid antisolvent precipitation of hydrophobic pharmaceutical nanoparticles in a microchannel reactor. Ind Eng Chem Res. 2007;46(24):8229–8235.
   Web of Science ®Google Scholar
• Chiou H, Chan H-K, Prud’homme RK, et al. Evaluation on the use of confined liquid impinging jets for the synthesis of nanodrug particles. Drug Dev Ind Pharm. 2008;34(1):59–64.
   PubMed Web of Science ®Google Scholar
• Chiou H, Chan H-K, Heng D, et al. A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation. J Aerosol Sci. 2008;39(6):500–509.
   Web of Science ®Google Scholar
• Chen T, D’Addio SM, Kennedy MT, et al. Protected peptide nanoparticles: experiments and brownian dynamics simulations of the energetics of assembly. Nano Lett. 2009;9(6):2218–2222.
   PubMed Web of Science ®Google Scholar
• Gindy ME, Panagiotopoulos AZ, Prud’homme RK. Composite block copolymer stabilized nanoparticles: simultaneous encapsulation of organic actives and inorganic nanostructures. Langmuir. 2008;24(1):83–90.
   PubMed Web of Science ®Google Scholar
• Karashima M, Sano N, Yamamoto S, et al. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations. Eur J Pharm Biopharm. 2017;115:65–72.
   PubMed Web of Science ®Google Scholar
• Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. 2002.
   Google Scholar
• Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4(4):403–416.
   PubMed Web of Science ®Google Scholar
• Chain H-K, Gonda I. Solid state characterization of spray-dried powders of recombinant human deoxyribonuclease (RhDNase). J Pharm Sci. 1998;87(5):647–654.
   PubMed Web of Science ®Google Scholar
• Andya JD, Maa Y-F, Costantino HR, et al. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody1. Pharm Res. 1999;16(3):350–358.
   PubMed Web of Science ®Google Scholar
• Ingvarsson PT, Yang M, Nielsen HM, et al. Stabilization of liposomes during drying. Expert Opin Drug Deliv. 2011;8(3):375–388.
   PubMed Web of Science ®Google Scholar
• Joshi MR, Misra A. Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech. 2001;2(4):44–53.
   Google Scholar
• Sadrzadeh N, Miller DP, Lechuga-Ballesteros D, et al. Solid-state stability of spray-dried insulin powder for inhalation: chemical kinetics and structural relaxation modeling of Exubera above and below the glass transition temperature. J Pharm Sci. 2010;99(9):3698–3710.
   PubMed Web of Science ®Google Scholar
• White S, Bennett DB, Cheu S, et al. EXUBERA®: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther. 2005;7(6):896–906.
   PubMedGoogle Scholar
• Chen L, Okuda T, Lu X-Y, et al. Amorphous powders for inhalation drug delivery. Adv Drug Deliv Rev. 2016;100:102–115.
   PubMed Web of Science ®Google Scholar
• Stevenson CL, Bennett DB. Development of the exubera® insulin pulmonary delivery system. Mucosal Delivery Biopharm. 2014;97814614952462014:461–481.
   Google Scholar
• Chang RY, Wong J, Mathai A, et al. Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection. Eur J Pharm Biopharm. 2017;121:1–13.
   PubMed Web of Science ®Google Scholar
• Chang RYK, Wallin M, Kutter E, et al. Storage stability of inhalable phage powders containing lactose at ambient conditions. Int J Pharm. 2019;560:11–18.
   PubMedGoogle Scholar
• Matinkhoo S, Lynch KH, Dennis JJ, et al. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J Pharm Sci. 2011;100(12):5197–5205.
   PubMed Web of Science ®Google Scholar
• Leung SSY, Parumasivam T, Gao FG, et al. Production of inhalation phage powders using spray freeze drying and spray drying techniques for treatment of respiratory infections. Pharm Res. 2016;33(6):1486–1496.
   PubMed Web of Science ®Google Scholar
• Chang RYK, Chen K, Wang J, et al. Proof-of-principle study in a murine lung infection model of Antipseudomonal activity of phage PEV20 in a dry-powder formulation. Antimicrob Agents Chemother. 2018;62:2.
   Web of Science ®Google Scholar
• Chang RYK, Wallin M, Lin Y, et al. Phage therapy for respiratory infections. Adv Drug Deliv Rev. 2018;133:76–86.
   PubMed Web of Science ®Google Scholar
• Chang RYK, Morales S, Okamoto Y, et al. Topical application of bacteriophages for treatment of wound infections. Transl Res. 2020;220:153–166.
   Web of Science ®Google Scholar
• Chang RYK, Das T, Manos J, et al. Bacteriophage PEV20 and ciprofloxacin combination treatment enhances Rremoval of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients. AAPS J. 2019;21(3):49.
   PubMed Web of Science ®Google Scholar
• Chang RYK, Kwok PCL, Khanal D, et al. Inhalable bacteriophage powders: glass transition temperature and bioactivity stabilization. Bioeng Transl Med. 2020;5(2):e10159.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Morton DAV, Yu HH, et al. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation. J Pharm Sci. 2013;102(10):3736–3747.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Gengenbach T, Denman JA, et al. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. AAPS J. 2014;16(1):37–47.
   PubMed Web of Science ®Google Scholar
• Chew NYK, Bagster DF, Chan H-K. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. Int J Pharm. 2000;206(1):75–83.
   PubMedGoogle Scholar
• Chew NYK, Shekunov BY, Tong HHY, et al. Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci. 2005;94(10):2289–2300.
   PubMed Web of Science ®Google Scholar
• Norderud Lærum B, Telg G, Stratelis G. Need of education for dry powder inhaler storage and retention – a patient-reported survey. Multidiscip Respir Med. 2016;11(1):21.
   PubMedGoogle Scholar
• Renswouw DC, Laarhoven AC, Haren MJ, et al. Storage instructions for inhalation capsules: consequences of incorrect storage and adherence in daily practice. J Pharm Pract. 2010;23(6):548–552.
   PubMedGoogle Scholar
• Price D, Summers M, Zanen P. Could interchangeable use of dry powder inhalers affect patients? Int J Clin Pract Suppl. 2005;149:3–6.
   PubMedGoogle Scholar
• Zografi G, Grandolfi GP, Kontny MJ, et al. Prediction of moisture transfer in mixtures of solids: transfer via the vapor phase. Int J Pharm. 1988;42(1):77–88.
   Web of Science ®Google Scholar
• Kontny MJ, Mulski CA. Gelatin capsule brittleness as a function of relative humidity at room temperature. Int J Pharm. 1989;54(1):79–85.
   Google Scholar
• Hochrainer D, Bechtold-Peters K, inventors; Google Patents, assignee. Capsules containing inhalable tiotropium. 2003.
   Google Scholar
• Al-Tabakha MM. HPMC capsules: current status and future prospects. J Pharm Pharm Sci. 2010;13(3):428–442.
   PubMed Web of Science ®Google Scholar
• Young PM, Crapper J, Philips G, et al. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2014;27(2):138–147.
   PubMed Web of Science ®Google Scholar
• Young PM, Salama RO, Zhu B, et al. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. Drug Dev Ind Pharm. 2015;41(5):859–865.
   PubMed Web of Science ®Google Scholar
• Borgstrom L, Asking L, Lipniunas P. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. J Aerosol Med. 2005;18(3):304–310.
   PubMedGoogle Scholar
• Lavorini F, Janson C, Braido F, et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13: 1753466619884532-1753466619884532.
   PubMed Web of Science ®Google Scholar
• Janson C, Loof T, Telg G, et al. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. NPJ Prim Care Respir Med. 2016;26:16053.
   PubMed Web of Science ®Google Scholar
• Trofast EA-C, Briggner L-E, inventors; Google Patents, assignee. Process for conditioning substances. 1998.
   Google Scholar
• Listiohadi YD, Hourigan JA, Sleigh RW, et al. Effect of milling on the caking behaviour of lactose. Aust J Dairy Technol. 2005;60(3):214–224.
   Google Scholar
• Muller T, Krehl R, Schiewe J, et al. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products. Eur J Pharm Biopharm. 2015;92:130–138.
   PubMed Web of Science ®Google Scholar
• Brodka-Pfeiffer K, Häusler H, Graß P, et al. Conditioning following powder micronization: influence on particle growth of salbutamol sulfate. Drug Dev Ind Pharm. 2003;29(10):1077–1084.
   PubMed Web of Science ®Google Scholar
• Weers JG, Miller DP, Tarara TE. Spray-dried PulmoSphere™ formulations for inhalation comprising crystalline drug particles. AAPS PharmSciTech. 2019;20(3):103.
   PubMed Web of Science ®Google Scholar
• McShane PJ, Weers JG, Tarara TE, et al. Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI): technical design and features of an efficient drug–device combination. Pulm Pharmacol Ther. 2018;50:72–79.
   PubMed Web of Science ®Google Scholar
• Chow MYT, Kwok PCL, Yang R, et al. Predicting the composition and size distribution of dry particles for aerosols and sprays of suspension: A Monte Carlo approach. Int J Pharm. 2020;582:119311.
   PubMedGoogle Scholar
• Gordon M, Taylor JS. Ideal copolymers and the second-order transitions of synthetic rubbers. i. non-crystalline copolymers. J Appl Chem. 1952;2(9):493–500.
   Web of Science ®Google Scholar
• Allison SD, Manning MC, Randolph TW, et al. Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran. J Pharm Sci. 2000;89(2):199–214.
   PubMed Web of Science ®Google Scholar
• Horn J, Tolardo E, Fissore D, et al. Crystallizing amino acids as bulking agents in freeze-drying. Eur J Pharm Biopharm. 2018;132:70–82.
   PubMed Web of Science ®Google Scholar
• Simperler A, Kornherr A, Chopra R, et al. Glass transition temperature of glucose, sucrose, and trehalose: an experimental and in silico study. J Phys Chem B. 2006;110(39):19678–19684.
   PubMed Web of Science ®Google Scholar
• Miller DP, Tan T, Tarara TE, et al. Physical characterization of tobramycin inhalation powder: I. rational design of a stable engineered-particle formulation for delivery to the lungs. Mol Pharm. 2015;12(8):2582–2593.
   PubMed Web of Science ®Google Scholar
• Porowska A, Dosta M, Fries L, et al. Predicting the surface composition of a spray-dried particle by modelling component reorganization in a drying droplet. Chem Eng Res Des. 2016;110:131–140.
   Web of Science ®Google Scholar
• Li L, Sun S, Parumasivam T, et al. l-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders. Eur J Pharm Biopharm. 2016;102:132–141.
   PubMed Web of Science ®Google Scholar
• Li L, Leung SSY, Gengenbach T, et al. Investigation of L-leucine in reducing the moisture-induced deterioration of spray-dried salbutamol sulfate power for inhalation. Int J Pharm. 2017;530(1):30–39.
   PubMedGoogle Scholar
• Gliniski J, Chavepeyer G, Platten JK. Surface properties of aqueous solutions of L-leucine. Biophys Chem. 2000;84(2):99–103.
   PubMed Web of Science ®Google Scholar
• Boraey MA, Hoe S, Sharif H, et al. Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol–water cosolvent system. Powder Technol. 2013;236:171–178.
   Web of Science ®Google Scholar
• Rabbani NR, Seville PC. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release. 2005;110(1):130–140.
   PubMed Web of Science ®Google Scholar
• Yu J, Chan H-K, Gengenbach T, et al. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders. Eur J Pharm Biopharm. 2017;119:224–234.
   PubMed Web of Science ®Google Scholar
• Sibum I, Hagedoorn P, Kluitman MPG, et al. Dispersibility and storage stability optimization of high dose isoniazid dry powder inhalation formulations with L-leucine or trileucine. Pharmaceutics. 2019;12(1):24.
   PubMed Web of Science ®Google Scholar
• Young PM, Cocconi D, Colombo P, et al. Characterization of a surface modified dry powder inhalation carrier prepared by “particle smoothing”. J Pharm Pharmacol. 2002;54(10):1339–1344.
   PubMed Web of Science ®Google Scholar
• Lau M, Young PM, Traini D. Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance. Drug Dev Ind Pharm. 2017;43(6):980–988.
   PubMed Web of Science ®Google Scholar
• Kumon M, Machida S, Suzuki M, et al. Application and mechanism of inhalation profile improvement of DPI formulations by mechanofusion with magnesium stearate. Chem Pharm Bull. 2008;56(5):617–625.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Qu L, Larson I, et al. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Int J Pharm. 2010;394(1–2):50–59.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Denman JA, Gengenbach T, et al. Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. J Pharm Sci. 2011;100(8):3421–3430.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Qu L, Gengenbach T, et al. Investigation of the extent of surface coating via mechanofusion with varying additive levels and the influences on bulk powder flow properties. Int J Pharm. 2011;413(1–2):36–43.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Qu L, Gengenbach T, et al. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS PharmSciTech. 2013;14(1):38–44.
   PubMed Web of Science ®Google Scholar
• Yu J, Romeo M-C, Cavallaro AA, et al. Protective effect of sodium stearate on the moisture-induced deterioration of hygroscopic spray-dried powders. Int J Pharm. 2018;541(1):11–18.
   PubMedGoogle Scholar
• Parlati C, Colombo P, Buttini F, et al. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res. 2009;26(5):1084–1092.
   PubMed Web of Science ®Google Scholar
• Iida K, Hayakawa Y, Okamoto H, et al. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem Pharm Bull (Tokyo). 2004;52(3):350–353.
   PubMed Web of Science ®Google Scholar
• Shetty N, Zeng L, Mangal S, et al. Effects of moisture-induced crystallization on the aerosol performance of spray dried amorphous ciprofloxacin powder formulations. Pharm Res. 2018;35(1):7.
   PubMed Web of Science ®Google Scholar
• Shetty N, Ahn P, Park H, et al. Improved physical stability and aerosolization of inhalable amorphous ciprofloxacin powder formulations by incorporating synergistic colistin. Mol Pharm. 2018;15(9):4004–4020.
   PubMedGoogle Scholar
• Shetty N, Park H, Zemlyanov D, et al. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation. Int J Pharm. 2018;544(1):222–234.
   PubMedGoogle Scholar
• Zhou QT, Loh ZH, Yu J, et al. How much surface Coating of hydrophobic azithromycin is sufficient to prevent moisture-induced decrease in aerosolisation of hygroscopic amorphous colistin powder? AAPS J. 2016;18(5):1213–1224.
   PubMed Web of Science ®Google Scholar
• Momin MAM, Tucker IG, Doyle CS, et al. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections. Int J Pharm. 2018;541(1):26–36.
   PubMedGoogle Scholar
• Mangal S, Xu R, Park H, et al. Understanding the impacts of surface compositions on the in-vitro dissolution and aerosolization of co-spray-dried composite powder formulations for inhalation. Pharm Res. 2018;36(1):6.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou QT, Sun SP, et al. Effects of surface composition on the aerosolisation and dissolution of inhaled antibiotic combination powders consisting of colistin and rifampicin. Aaps J. 2016;18(2):372–384.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Sun SP, Chan JG, et al. Novel inhaled combination powder containing amorphous colistin and crystalline rifapentine with enhanced antimicrobial activities against planktonic cells and biofilm of Pseudomonas aeruginosa for respiratory infections. Mol Pharm. 2015;12(8):2594–2603.
   PubMedGoogle Scholar
• Lu W, Rades T, Rantanen J, et al. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying. Int J Pharm. 2019;565:1–8.
   PubMedGoogle Scholar
• Lu W, Rades T, Rantanen J, et al. Amino acids as stabilizers for spray-dried simvastatin powder for inhalation. Int J Pharm. 2019;572:118724.
   PubMedGoogle Scholar
• Budesonide [Internet]. National Center for Biotechnology Information, PubChem Database. [cited 2020 Jul 09]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Budesonide-section=Solubility
   Google Scholar
• Arginine [Internet]. National Center for Biotechnology Information, PubChem Database. [cited 2020 Jul 09]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Arginine-section=Solubility
   Google Scholar